ClinicalTrials.gg
RecruitingNCT07145918Updated Sep 15, 2026

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

A Phase 2 interventional study of Emraclidine and Placebo in Schizophrenia, sponsored by AbbVie. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.

Planned enrollment
13th of 27
268 · median 268
Started
2025
the only one that year
Phase 2
13 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies in Schizophrenia by AbbVie, this one is the 13th largest by planned enrollment, is the only one that started in 2025, is one of 13 in phase 2, and was the 27th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by AbbVie, or all of them as a file.
02

Study summary

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia

Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 268 participants will be enrolled across roughly 32 sites in the United States.

Participants in Part A will be assigned to oral emraclidine or placebo administered for 14 days or up to 21 days depending on cohort. Cohorts without titration include a 14-day treatment period at target dose. Cohorts with titration are comprised of a titration period of up to 7 days and a 14-day treatment period at the cohort target dose. Participants in Part B will receive oral emraclidine or placebo. Participants will be followed for 30 days after the last dose of the study drug.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • ABBV-1231
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • within 18 to 40 kg/m2 (inclusive of both values), and body weight > 50 kg (110 lbs).
  • (Part A only): Positive and Negative Syndrome Scale (PANSS) total score \< 80 at Screening and at Baseline
  • (Part B only): Participant experiencing an acute exacerbation of psychotic symptoms with onset less than 2 months prior to Screening
  • (Part B only): Participant must have a PANSS total score from 80 to 120, inclusive, at Screening and at Baseline
  • (Part B only): Participant MUST have a score of ≥ 4 (moderate or greater) for ≥ 2 of the following PANSS Positive Scale items at Screening and at Baseline
  • (Part B only): Participant must have a Clinical Global Impression of Severity (CGIS) score ≥ 4 (at least moderately ill) at Screening and Baseline

Exclusion criteria

Exclusion Criteria:

  • Any primary disorder other than schizophrenia (current nicotine use disorder and caffeine use disorder are allowed) within 12 months before Screening.
  • History of clozapine exposure.
  • History of treatment resistance to schizophrenia medications, defined as failure to respond to 2 or more adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) within the last 12 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
268 participants (estimated)

Study arms

  • Experimental
    Emraclidine Part A

    Participants will be assigned to receive one of multiple ascending doses of oral emraclidine for 14 or up to 21 days, followed by a 30-day safety follow-up period.

    Drug: Emraclidine

  • Experimental
    Placebo-Part A

    Participants will be assigned to receive one of multiple ascending doses of oral placebo for 14 or up to 21 days, followed by a 30-day safety follow-up period.

    Drug: Placebo

  • Experimental
    Emraclidine-Part B

    Participants will receive oral emraclidine for 42 days followed by a 30-day safety follow-up period.

    Drug: Emraclidine

  • Experimental
    Placebo-Part B

    Participants will receive placebo for 42 days followed by a 30-day safety follow-up period.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to approximately 74 days

  2. Part A Only-Maximum Observed Plasma Concentration (Cmax) of Emraclidine

    Cmax of Emraclidine

    Time frame: Up to approximately 24 days

  3. Part A Only-Time to Cmax (Tmax) of Emraclidine

    Tmax of Emraclidine

    Time frame: Up to approximately 24 days

  4. Part A Only-Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) of Emraclidine

    AUCt of Emraclidine

    Time frame: Up to approximately 24 days

  5. Part A Only-Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Emraclidine

    AUCtau of Emraclidine

    Time frame: Up to approximately 24 days

  6. Part A Only- Minimum plasma concentration (Cmin) of Emraclidine

    Cmin of Emraclidine

    Time frame: Up to approximately 21 days

  7. Part A Only-Average plasma concentration (Cavg) of Emraclidine

    Cavg of Emraclidine

    Time frame: Up to approximately 21 days

  8. Part A Only- Terminal Phase Elimination Half-Life (t1/2) of Emraclidine

    Terminal phase elimination half-life of Emraclidine

    Time frame: Up to approximately 21 days

  9. Part A Only-Terminal elimination rate constant (λz) of Emraclidine

    λz of Emraclidine

    Time frame: Up to approximately 21 days

  10. Part A Only-Apparent Clearance of Drug from Plasma (CL/F) of Emraclidine

    CL/F of Emraclidine

    Time frame: Up to approximately 21 days

  11. Part A Only-Apparent Volume of Distribution DuringTerminal Phase (Vz/F) of Emraclidine

    Vz/F of Emraclidine

    Time frame: Up to approximately 21 days

  12. Part A Only-Peak-to-trough ratio (PTR) of Emraclidine

    PTR of Emraclidine

    Time frame: Up to approximately 21 days

  13. Part A Only- Accumulation ratio for Cmax (RacCmax) of Emraclidine

    RacCmax of Emraclidine

    Time frame: Up to approximately 21 days

  14. Part A Only-Accumulation ratio for AUCtau (RacAUCtau) of Emraclidine

    RacAUCtau of Emraclidine

    Time frame: Up to approximately 21 days

  15. Part A Only-Maximum Observed Plasma Concentration (Cmax) of Metabolite (CV-0000364)

    Cmax of Metabolite (CV-0000364)

    Time frame: Up to approximately 24 days

  16. Part A Only-Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Metabolite (CV-000036)

    AUCtau of Metabolite (CV-000036)

    Time frame: Up to approximately 24 days

  17. Part A Only-Time to Cmax (Tmax) of Metabolite (CV-0000364)

    Tmax of Metabolite (CV-0000364)

    Time frame: Up to approximately 24 days

  18. Part A Only-Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) Metabolite (CV-000036)

    AUCt of Metabolite (CV-000036)

    Time frame: Up to approximately 24 days

  19. Part A Only-Metabolite to Parent Ratio (MRCmax) of Metabolite (CV-0000364) calculated from Cmax

    MRCmax of Metabolite (CV-000036)

    Time frame: Up to approximately 21 days

  20. Part A Only- Metabolite to Parent Ratio (MRAUCtau) of Metabolite (CV-0000364)

    MRAUCtau of Metabolite (CV-0000364)

    Time frame: Up to approximately 21 days

  21. Part A Only- Terminal Phase Elimination Half-Life (t1/2) of of Metabolite (CV-0000364)

    Terminal phase elimination half-life of Metabolite (CV-0000364)

    Time frame: Up to approximately 21 days

  22. Part A Only-Terminal elimination rate constant (λz) of Metabolite (CV-0000364)

    λz of Metabolite (CV-0000364)

    Time frame: Up to approximately 21 days

  23. Part A Only-Peak-to-trough ratio (PTR) of Metabolite (CV-0000364)

    PTR of Metabolite (CV-0000364)

    Time frame: Up to approximately 21 days

  24. Part B Only-Change from Baseline in Positive and Negative Syndrome Scale (PANSS) total score

    PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

    Time frame: Up to approximately week 6

  25. Part B Only-Maximum Observed Plasma Concentration (Cmax) of Emraclidine

    Cmax of Emraclidine

    Time frame: Up to approximately 24 days

  26. Part B Only-Time to Cmax (Tmax) of Emraclidine

    Tmax of Emraclidine

    Time frame: Up to approximately 24 days

  27. Part B Only-Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) of Emraclidine

    AUCt of Emraclidine

    Time frame: Up to approximately 24 days

  28. Part B Only-Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Emraclidine

    AUCtau of Emraclidine

    Time frame: Up to approximately 24 days

Secondary outcomes

  1. Part B Only-Change from Baseline in in Clinical Global Impression of Severity (CGIS) score

    CGIS is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from "normal, to at all ill" (1) to "among the most extremely ill patients" (5), with higher scores indicating greater anxiety severity.

    Time frame: Up to approximately Week 6

  2. Part B Only-Change from Baseline in Positive and Negative Syndrome Scale (PANSS) total score

    PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

    Time frame: Up to approximately 74 days

  3. Part B Only-Change from Baseline in in Clinical Global Impression of Severity (CGIS) score

    CGIS is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from "normal, to at all ill" (1) to "among the most extremely ill patients" (5), with higher scores indicating greater anxiety severity.

    Time frame: Up to approximately 53 days

  4. Part B Only-Number of Participants achieving ≥ 30% improvement in PANSS total score

    PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

    Time frame: Up to approximately week 6

  5. Part B Only-Number of Participants achieving remission (PANSS total score ≤ 60)

    PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

    Time frame: Up to approximately week 6

07

Study locations

7 of 7 sites recruiting
  • Woodland International Research Group /ID# 275747
    Little Rock, Arkansas 72211, United States
    Recruiting
    • Site Coordinator · Contact501-221-8681
  • California Clinical Trials Medical Group - Parexel /ID# 275751
    Glendale, California 91206, United States
    Recruiting
    • Site Coordinator · Contact818-254-1600
  • CenExel Collaborative Neuroscience Research /ID# 273005
    Los Alamitos, California 90720, United States
    Recruiting
  • Cbh Health - Gaithersburg /ID# 272932
    Gaithersburg, Maryland 20877, United States
    Recruiting
    • Site Coordinator · Contact301-251-4702
  • Cenexel Hassman Research Institute (Hri) /ID# 276128
    Marlton, New Jersey 08053, United States
    Recruiting
    • Site Coordinator · Contact888-437-4104
  • Community Clinical Research - Cross Park Drive /ID# 272977
    Austin, Texas 78754, United States
    Recruiting
    • Site Coordinator · Contact512-323-2622
  • Pillar Clinical Research - Richardson /ID# 275715
    Richardson, Texas 75080, United States
    Recruiting
    • Site Coordinator · Contact214-396-4844
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2028, 30 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 30 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 28, 2025
StartActual
Aug 4, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145918
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Aug 4, 2025
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion